Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6696481 | ADHERA | Salt of perindopril and pharmaceutical compositions containing it |
Apr, 2023
(18 days from now) | |
US7846961 | ADHERA | α crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it |
Oct, 2029
(6 years from now) |
Market Authorisation Date: 21 January, 2015
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
4
France
3
Australia
3
Korea, Republic of
2
South Africa
2
Denmark
2
Hong Kong
2
Slovenia
2
Morocco
2
Norway
2
United States
2
Brazil
2
Croatia
2
Spain
2
Poland
2
China
2
Georgia
2
Ukraine
2
Japan
2
EA
2
Canada
2
New Zealand
2
ME
2
European Union
1
Israel
1
OA
1
Turkey
1
Austria
1
Mexico
1
Hungary
1
Costa Rica
1
AP
1
Germany
1
Argentina
1
Portugal
1
Cyprus
1
Yugoslavia
1
Malaysia
1
Iceland
1
RS
1
Ecuador
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic